P2RY8在肝细胞癌组织中表达的生物信息学分析及其临床意义
DOI: 10.3969/j.issn.1001-5256.2022.08.020
A bioinformatics analysis of P2RY8 expression in hepatocellular carcinoma and its clinical significance
-
摘要:
目的 本研究旨在探讨人B淋巴细胞限制受体P2RY8在肝细胞癌(HCC)诊断和预后中的应用价值,并分析了其与肿瘤免疫的关系。 方法 利用肿瘤基因组图谱(TCGA)数据库比较P2RY8的表达情况。采用R软件包分析P2RY8与肿瘤分期的相关性,建立诊断及生存的受试者工作特征(ROC)曲线和Nomogram模型。利用肿瘤免疫评估资源(TIMER)分析免疫细胞浸润、免疫细胞生物标志物和免疫检查点。使用STRING数据库分析蛋白质-蛋白质相互作用网络信息。通过基因本体论(GO)分析和京都基因与基因组百科全书(KEGG)分析P2RY8及其互作基因的功能。收集2007年6月—2008年11月行肝癌根治性手术的64例患者HCC组织及其中35例对应的癌旁组织(组织芯片购自上海芯超生物科技有限公司)进行验证,统计其临床资料及随访资料,采用免疫组化法检测HCC及癌旁组织标本中P2RY8的表达情况。符合正态分布的计量资料两组间比较采用t检验;非正态分布的计量资料两组间比较采用Mann-Whitney U检验,多组间比较采用Kruskal-Wallis H检验。计数资料两组间比较采用χ2检验。两变量间的相关性采用Spearman相关分析。应用Kaplan-Meier绘制生存曲线,log-rank检验计算生存率。 结果 P2RY8在HCC中过表达,可通过P2RY8的表达水平准确鉴别肿瘤与正常组织(ROC曲线下面积为0.794)。P2RY8高表达的患者预后较好(P=0.005)。64例临床样本数据同样证实P2RY8高表达的肝癌患者术后3年生存率(78.9% vs 46.2%,P=0.007)、5年生存率(76.3% vs 38.5%,P=0.002)和OS[92.5(48.8~102.0)个月vs 33.0(25.0~95.5)个月,P=0.022]显著高于低表达者,Kaplan-Meier生存曲线进一步表明P2RY8表达水平与HCC患者预后相关。此外,P2RY8在HCC中与免疫细胞浸润和免疫检查点呈正相关。GO/KEGG通路富集分析显示P2RY8在体液免疫、细胞免疫等信号转导通路中均有富集。 结论 P2RY8不仅参与了HCC的发生发展,还参与其免疫调节。因此,P2RY8可以作为一个潜在的HCC诊断和预后的生物标志物和治疗靶点。 -
关键词:
- 癌,肝细胞 /
- 人B淋巴细胞限制受体P2RY8 /
- 肿瘤基因组图谱 /
- 生物标记
Abstract:Objective To investigate the application value of the human B cell-confinement receptor P2RY8 in the diagnosis and prognosis of hepatocellular carcinoma (HCC) and its association with tumor immunity. Methods The Cancer Genome Atlas database was used to compare the expression of P2RY8. R software package was used to analyze the correlation between P2RY8 and tumor staging, and the receiver operating characteristic (ROC) curve and a nomogram model were established for diagnosis and survival. Tumor Immune Evaluation Resource was used to analyze immune cell infiltration, immune cell biomarkers, and immune checkpoints. STRING database was used to analyze protein-protein interaction network information. Gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were used to analyze the function of P2RY8 and its interacting genes. For the purpose of validation, HCC tissue samples were collected from 64 patients who underwent radical surgery for HCC from June 2007 to November 2008, and the corresponding adjacent tissue samples were collected from 35 patients out of these patients (tissue chips were purchased from Shanghai Outdo Biotech Co., Ltd.); related clinical data and follow-up data were analyzed, and immunohistochemistry was used to measure the expression of P2RY8 in HCC and adjacent tissue samples. The t-test was used for comparison of normally distributed continuous data between two groups; the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups, and the Kruskal-Wallis H test was used for comparison between multiple groups. The chi-square test was used for comparison of categorical data between two groups. A Spearman correlation analysis was used to investigate the correlation between two variables. The Kaplan-Meier method was used to plot survival curves, and the log-rank test was used to calculate survival rates. Results P2RY8 was overexpressed in HCC, and the expression level of P2RY8 could accurately differentiate tumor from normal tissue, with an area under the ROC curve of 0.794. The patients with a higher expression level of P2RY8 tended to have a better prognosis (P=0.005). The data from 64 clinical samples also confirmed that compared with the patients with a low expression level of P2RY8, the patients with a high expression level of P2RY8 had significantly higher 3-year survival rate (78.9% vs 46.2%, P=0.007), 5-year survival rate (76.3% vs 38.5%, P=0.002), and overall survival time [92.5 (48.8-102.0) months vs 33.0 (25.0-95.5) months, P=0.022], and the Kaplan-Meier survival curve further indicated that the expression level of P2RY8 was associated with the prognosis of HCC patients. In addition, P2RY8 was positively correlated with immune cell infiltration and immune checkpoint in HCC. The GO/KEGG pathway enrichment analyses showed that P2RY8 was enriched in the signal transduction pathways such as humoral immunity and cellular immunity. Conclusion P2RY8 participates in the development, progression, and immune regulation of HCC, and therefore, P2RY8 can serves as a potential biomarker and a therapeutic target for the diagnosis and prognosis of HCC. -
Key words:
- Carcinoma, Hepatocellular /
- Human B cell restriction receptor P2RY8 /
- TCGA /
- Biomarkers
-
表 1 TCGA数据库中HCC的单因素和多因素生存分析
Table 1. Univariate and multivariate survival analysis of hepatocellular carcinoma
参数 例数 单因素分析 多因素分析 HR(95%CI) P值 HR(95%CI) P值 T分期 370 T1 183 T2 94 1.428 (0.901~2.264) 0.129 1.558 (0.865~2.808) 0.140 T3+T4 93 2.949 (1.982~4.386) <0.001 3.031 (1.832~5.016) <0.001 N分期 258 N0 254 N1 4 2.029 (0.497~8.281) 0.324 M分期 272 M0 268 M1 4 4.077 (1.281~12.973) 0.017 2.769 (0.826~9.283) 0.099 P2RY8 373 0.766 (0.627~0.935) 0.009 0.754 (0.589~0.966) 0.025 表 2 HCC中P2RY8表达与免疫细胞标志物的相关性分析
Table 2. Correlation analysis of P2RY8 expression and immune cell markers in hepatocellular carcinoma
免疫细胞 生物标志物 r值 P值 B淋巴细胞 CD19 0.271 <0.001 CD20(KRT20) -0.040 0.443 CD38 0.315 <0.001 CD8+T淋巴细胞 CD8A 0.379 <0.001 CD8B 0.321 <0.001 Tfh BCL6 0.086 0.095 ICOS 0.364 <0.001 CXCR5 0.300 <0.001 Th1 T-bet(TBX21) 0.451 <0.001 STAT1 0.250 <0.001 STAT4 0.237 <0.001 IL12RB2 0.267 <0.001 WSX1(IL27RA) 0.290 <0.001 IFNγ(IFNG) 0.230 <0.001 TNFα(TNF) 0.259 <0.001 Th2 CCR3 0.064 0.215 GATA3 0.369 <0.001 STAT5A 0.375 <0.001 STAT6 0.149 0.004 Th9 IRF4 0.390 <0.001 PU.1(SPI1) 0.346 <0.001 TGFBR2 0.444 <0.001 Th17 IL-17A 0.127 0.014 IL-21R 0.369 <0.001 IL-23R 0.279 <0.001 STAT3 0.269 <0.001 Th22 AHR 0.109 0.035 CCR10 0.110 0.034 Treg CCR8 0.332 <0.001 CD25(IL2RA) 0.336 <0.001 FOXP3 0.194 <0.001 M1巨噬细胞 COX2(PTGS2) 0.408 <0.001 INOS(NOS2) 0.247 <0.001 IRF5 0.147 0.004 M2巨噬细胞 ARG1 0.013 0.795 CD206(MRC1) 0.376 <0.001 CD115(CSF1R) 0.420 <0.001 肿瘤相关巨噬细胞 PDCD1LG2 0.466 <0.001 CD80 0.315 <0.001 CD40 0.132 0.011 TLR7 0.400 <0.001 自然杀伤细胞 CD7 0.230 <0.001 KIR3DL1 0.271 <0.001 XCL1 0.146 0.005 中性粒细胞 CD11b(ITGAM) 0.174 <0.001 CD15(FUT4) 0.151 0.004 CD66b(CEACAM8) -0.039 0.456 树突状细胞 CD1C 0.439 <0.001 CD11c(ITGAX) 0.336 <0.001 CD141(THBD) 0.537 <0.001 表 3 64例HCC患者中P2RY8表达水平与临床特征及预后之间的关系
Table 3. The relationship between P2RY8 expression level and clinical characteristics and outcomes in 64 HCC patients
参数 P2RY8表达水平 统计值 P值 高表达组(n=38) 低表达组(n=26) 年龄(岁) 52.3±9.0 53.0±10.4 t=0.318 0.751 男[例(%)] 34(89.5) 22(84.6) χ2=0.333 0.564 既往HBV或HCV感染[例(%)] 31(81.6) 21(80.8) χ2=0.804 0.804 肝硬化[例(%)] 33(86.8) 23(88.5) χ2=0.406 0.524 AFP(μg/L) 122.5(7.8~929.5) 242.0(6.5~3133.0) Z=-0.548 0.584 TBil(μmol/L) 12.3(9.9~20.9) 13.0(10.4~16.5) Z=-0.358 0.720 ALT(U/L) 38.0(24.0~71.8) 41.0(21.0~70.0) Z=-0.499 0.618 GGT(U/L) 46.0(31.8~108.8) 69.0(40.5~105.0) Z=-1.131 0.258 Alb(g/dL) 4.4±0.6 4.2±0.4 t=1.286 0.203 肿瘤数目>1[例(%)] 3(7.9) 3(11.5) χ2=0.241 0.623 肿瘤大小(cm) 3.0(2.0~5.3) 6.0(3.8~8.3) Z=-3.030 0.002 TNM分期Ⅱ~Ⅲ期[例(%)] 9(23.7) 10(38.5) χ2=1.615 0.204 1年生存[例(%)] 37(97.4) 23(88.5) χ2=2.090 0.148 3年生存[例(%)] 30(78.9) 12(46.2) χ2=7.359 0.007 5年生存[例(%)] 29(76.3) 10(38.5) χ2=9.293 0.002 PFS(月) 47.0(14.0~54.0) 21.0(8.0~53.0) Z=-1.068 0.285 OS(月) 92.5(48.8~102.0) 33.0(25.0~95.5) Z=-2.295 0.022 -
[1] MCGLYNN KA, PETRICK JL, LONDON WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability[J]. Clin Liver Dis, 2015, 19(2): 223-238. DOI: 10.1016/j.cld.2015.01.001. [2] SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. [3] COURI T, PILLAI A. Goals and targets for personalized therapy for HCC[J]. Hepatol Int, 2019, 13(2): 125-137. DOI: 10.1007/s12072-018-9919-1. [4] KANWAL F, SINGAL AG. Surveillance for hepatocellular carcinoma: current best practice and future direction[J]. Gastroenterology, 2019, 157(1): 54-64. DOI: 10.1053/j.gastro.2019.02.049. [5] KIRKIN V, DIKIC I. Ubiquitin networks in cancer[J]. Curr Opin Genet Dev, 2011, 21(1): 21-28. DOI: 10.1016/j.gde.2010.10.004. [6] TANDON P, GARCIA-TSAO G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies[J]. Liver Int, 2009, 29(4): 502-510. DOI: 10.1111/j.1478-3231.2008.01957.x. [7] EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2. [8] YAU T, PARK JW, FINN RS, et al. CheckMate 459: A randomized, multi-center phase Ⅲ study of nivolumab (NⅣO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)[J]. Ann Oncol, 2019, 30(5_suppl): 874-875. DOI: 10.1093/annonc/mdz394.029. [9] FINN RS, RYOO BY, MERLE P, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC)[J]. J Clin Oncol, 2019, 37(15_suppl): 4004. DOI: 10.1200/JCO.2019.37.15_suppl.4004. [10] SCHMITZ R, WRIGHT GW, HUANG DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma[J]. N Engl J Med, 2018, 378(15): 1396-1407. DOI: 10.1056/NEJMoa1801445. [11] MUPPIDI JR, SCHMITZ R, GREEN JA, et al. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma[J]. Nature, 2014, 516(7530): 254-258. DOI: 10.1038/nature13765. [12] MUPPIDI JR, LU E, CYSTER JG. The G protein-coupled receptor P2RY8 and follicular dendritic cells promote germinal center confinement of B cells, whereas S1PR3 can contribute to their dissemination[J]. J Exp Med, 2015, 212(13): 2213-2222. DOI: 10.1084/jem.20151250. [13] LU E, WOLFREYS FD, MUPPIDI JR, et al. S-Geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8[J]. Nature, 2019, 567(7747): 244-248. DOI: 10.1038/s41586-019-1003-z. [14] PAGE EC, HEATLEY SL, EADIE LN, et al. HMGN1 plays a significant role in CRLF2 driven down syndrome leukemia and provides a potential therapeutic target in this high-risk cohort[J]. Oncogene, 2022, 41(6): 797-808. DOI: 10.1038/s41388-021-02126-4. [15] AYPAR U, TAYLOR J, GARCIA JS, et al. P2RY8-CRLF2 fusion-positive acute myeloid leukemia with myelodysplasia-related changes: response to novel therapy[J]. JCO Precis Oncol, 2020, 4: 152-160. DOI: 10.1200/PO.19.00294. [16] TOMCZAK K, CZERWIŃSKA P, WIZNEROWICZ M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge[J]. Contemp Oncol (Pozn), 2015, 19(1A): A68-A77. DOI: 10.5114/wo.2014.47136. [17] RAVI R, NOONAN KA, PHAM V, et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy[J]. Nat Commun, 2018, 9(1): 741. DOI: 10.1038/s41467-017-02696-6. [18] JIANG P, GU S, PAN D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response[J]. Nat Med, 2018, 24(10): 1550-1558. DOI: 10.1038/s41591-018-0136-1. [19] HE Y, GALLMAN AE, XIE C, et al. P2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance[J]. J Exp Med, 2022, 219(1): 7-33. DOI: 10.1084/jem.20211004. [20] GREAVES SA, PETERSON JN, STRAUCH P, et al. Active PI3K abrogates central tolerance in high-avidity autoreactive B cells[J]. J Exp Med, 2019, 216(5): 1135-1153. DOI: 10.1084/jem.20181652. [21] BOUMA G, BURNS SO, THRASHER AJ. Wiskott-Aldrich Syndrome: Immunodeficiency resulting from defective cell migration and impaired immunostimulatory activation[J]. Immunobiology, 2009, 214(9-10): 778-790. DOI: 10.1016/j.imbio.2009.06.009. [22] BOURNAZOS S, CORTI D, VIRGIN HW, et al. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection[J]. Nature, 2020, 588(7838): 485-490. DOI: 10.1038/s41586-020-2838-z. -
8期单独排.pdf